Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2026 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026

Data will be presented in two top-rated oral presentationsMeet the Expert session offers insights into Actinium-225 production Garching / Munich, October 7, 2026 — ITM Isotope Technologies Munich SE...
September 27, 2026 16:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ¹⁷⁷Luedotreotide (ITM-11) in GEP-NETs at ASTRO 2026

Investigator-led SwissNET registry analysis showed longer real-world progression-free and overall survival for patients re-treated with 177Lu-edotreotide compared to those receiving...
September 23, 2026 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026

Garching / Munich, September 23, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM,...
August 10, 2026 10:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Receives Complete Response Letter for ¹⁷⁷Lu-edotreotide (ITM-11)

No clinical safety or efficacy issues identified and no additional clinical or nonclinical data requestedThe Complete Response Letter for the ongoing ITM-11 New Drug Application (NDA) cites Chemistry,...
July 27, 2026 05:21 ET | Source: ITM Isotope Technologies Munich SE

ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division

Lumara Bio brings together ITM's existing pipeline of early- and late-stage radiopharmaceutical therapies, including lead drug candidate 177Lu-edotreotide (ITM-11), into a single, dedicated...
July 07, 2026 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs

Investigational n.c.a. 177Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs. everolimus Garching / Munich, July 7, 2026 – ITM...
June 29, 2026 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients

Patient enrollment has been completed; all enrolled patients remain aliveData presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium Garching/Munich and Münster, Germany...
June 01, 2026 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026

Analysis from the Phase 3 COMPETE trial suggests population-based modeling may enable accurate individualized dosimetry with substantially fewer imaging requirements Los Angeles, California, June 1,...
May 30, 2026 13:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotideData build upon previously reported COMPETE...
May 19, 2026 08:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium

Garching / Munich, May 19, 2026 –– ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that dosimetry data from its Phase 3 COMPETE trial will be...